Fresenius Medical Care AG & Co. KGaA (FMS) Stock Score, Valuation & Financial Research
Fresenius Medical Care AG & Co. KGaA is in the Healthcare sector and Medical - Care Facilities industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 41/100.
Quick answer for FMS
Fresenius Medical Care AG & Co. KGaA currently has a Wall Street Score of 41/100. The stored market price is $22.96. Its financial score is 31/100. Its valuation score is 26/100. These figures are a research snapshot, not a buy or sell recommendation.
What Fresenius Medical Care AG & Co. KGaA does
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfoli
FMS financial snapshot
- Wall Street Score:
- 41/100
- Current price:
- $22.96
- Market capitalization:
- $12.33B
- Revenue:
- $22.58B
- Net income:
- $1.09B
- Free cash flow:
- $1.97B
- Cash:
- $1.23B
- Total debt:
- $12.74B
- EPS:
- 1.94
- P/E ratio:
- 11.8x
- Financial score:
- 31/100
- Valuation score:
- 26/100
- Revenue score:
- 30/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $1.97B, showing positive cash generation.
- The balance sheet shows $1.23B of cash versus $12.74B of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 26/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 31/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research FMS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.